Kuraray Signs US Distribution Agreement with Gehring-Montgomery
05 Apr 2023
License out/in
Kuraray has a new distribution partner for MOWITAL in North America. From July 1, 2023, Gehring-Montgomery, Inc. will include Kuraray’s range of MOWITAL polyvinyl butyral (PVB) resins in its portfolio of resins and chemicals for the North American market.
Gehring-Montgomery is the US subsidiary of the TER Group, a global distributor of fine and specialty chemicals headquartered in Hamburg, Germany. The distribution agreement with Gehring-Montgomery will increase the global reach of the PVB resins offered by Kuraray, particularly for printing inks, adhesives, paints and coatings for the US market.
Kuraray markets a unique range of PVB materials under the MOWITAL brand. As the European market leader for technical PVB applications, Kuraray specializes in high-quality, high-performance global products for the synthetics, electronics, coatings and packaging industries. Kuraray has a strong sustainability policy and is committed to using renewable raw materials and reducing its environmental footprint. PVB resins are important in many areas, from coatings and printing inks to adhesives, high-performance ceramics, films, coatings and 3D printing.
Gehring-Montgomery, Inc. (GMI), is based in Warminster, PA and is continuing to grow in the US, with offices and warehouses in Pennsylvania, Florida, Georgia, Illinois, South Carolina and Louisiana. It has been awarded gold status by EcoVadis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.